APLS:NSD-Apellis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 48.81

Change

0.00 (0.00)%

Market Cap

USD 3.92B

Volume

0.73M

Average Target Price

USD 62.00 (+27.02%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.11B 20.60 15.08
MRNA Moderna, Inc

N/A

USD52.85B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

N/A

USD49.45B 15.12 11.87
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.00B 55.18 32.28
BGNE BeiGene, Ltd

N/A

USD28.45B N/A N/A
SGEN Seagen Inc

N/A

USD27.06B 44.32 37.70
RPRX Royalty Pharma plc

N/A

USD25.83B 22.60 15.41
BNTX BioNTech SE

N/A

USD23.16B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD20.42B 26.59 3.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.67% 18% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.67% 18% F 10% F
Trailing 12 Months  
Capital Gain 41.77% 59% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.77% 59% F 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 28.75% 65% D 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.75% 64% D 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 49.17% 58% F 28% F
Risk Adjusted Return 58.46% 84% B 77% C+
Market Capitalization 3.92B 89% B+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 36.25 5% F 5% F
Price / Cash Flow Ratio -24.44 79% C+ 85% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -288.86% 8% F 3% F
Return on Invested Capital -2.09% 86% B 44% F
Return on Assets -19.79% 66% D 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.25 7% F 4% F
Short Percent 14.53% 13% F 12% F
Beta 1.52 45% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.